Skip to main content

Generate Biomedicines, Inc.

corporate_fare Company Profile

Generate Biomedicines, Inc.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed GENB - Latest Insights

GENB
Mar 02, 2026, 5:52 PM EST
Filing Type: 4
Importance Score:
10
Director & 10% Owner Buys $75M in Stock at 28% Premium Post-IPO
Sentiment: Positive
View Wiseek Article
GENB
Mar 02, 2026, 5:50 PM EST
Filing Type: 4
Importance Score:
8
Director Stephane Bancel Converts $9.05M in Preferred Stock to Common Shares Post-IPO
Sentiment: Neutral
View Wiseek Article
GENB
Mar 02, 2026, 5:22 PM EST
Filing Type: 8-K
Importance Score:
7
Generate Biomedicines Amends Charter & Bylaws Post-IPO, Authorizes 500M Common Shares
Sentiment: Negative
View Wiseek Article
GENB
Feb 27, 2026, 5:16 PM EST
Filing Type: 424B4
Importance Score:
8
Generate Biomedicines Completes IPO, Securing $368.8M to Fund Pipeline & Extend Runway
Sentiment: Positive
View Wiseek Article